Amendment to Paid-in Capital Increase Decision
한국유니온제약
080720
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2632
Risk-adjusted indicator based on 2632 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Paid-in Capital Increase (details not available)
AI Analysis Summary
UNION KOREA PHARM CO.,Ltd announced an amendment to its decision on a paid-in capital increase. While specific financial figures for the increase are not available, a paid-in capital increase typically leads to share dilution, which can negatively impact existing shareholder value. The amendment suggests potential changes to the terms or scale of the original capital increase plan.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.